Tanya joined Karyopharm in October 2018 and is responsible for the company’s regulatory affairs strategy and operations.
Tanya is an accomplished regulatory professional with more than 20 years of experience in global drug development across a variety of therapeutic areas, including oncology, neurology, cardiovascular, pulmonology, rheumatology and metabolism. Additionally, she has significant regulatory experience across all phases of drug development, including with products targeting orphan diseases. Tanya has built multidisciplinary departments addressing regulatory affairs strategy, operations, legal representation, quality assurance and medical writing.
Prior to joining Karyopharm, Tanya held leadership positions at Idera, Tesaro, Seaside, Vion, Millennium and Syros and was instrumental in developing the approval strategy and leading interactions with U.S. and European regulators for clinical trials, marketing applications (including ODAC presentations) and drug labeling. Tanya’s past accomplishments include the successful negotiations for registration trial designs, approval, and/or commercialization of VELCADE®, VARUBI®, INTEGRILIN® and ZEJULA®. In November 2020, Tanya was appointed to the board of directors of Replimune Inc.
Tanya holds a Bachelor of Science degree in Biology from Northeastern University and a Master of Science degree in Regulatory Affairs and Public Health from Massachusetts College of Pharmacy and Allied Health Science.